NCT02929394 - Trabectedin Maintenance Post 1st-line in STS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 7, 2017

Primary Completion Date

June 5, 2020

Study Completion Date

June 5, 2020

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG

Trabectedin

Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity

Trial Locations (14)

13385

Assistance Publique - Hopitaux de Marseille - Hôpital de La Timone, Marseille

28040

Hospital Universitario San Carlos, Madrid

30625

Medizinische Hochschule Hannover, Hanover

33076

Institut Bergonie, Bordeaux

59020

Centre Oscar Lambret, Lille

68167

UniversitaetsMedizin Mannheim, Mannheim

69008

Centre Leon Berard, Lyon

75248

Institut Curie, Paris

94805

Gustave Roussy, Villejuif

Unknown

Leiden University Medical Center, Leiden

02 781

Maria Sklodowska-Curie Memorial Cancer Centre, Warsaw

08907

Institut Catala d'Oncologia - ICO L'Hospitalet - Hospital Duran i Reynals, Barcelona

08916

Institut Catala d'Oncologia - ICO Badalona - Hospital Germans Trias i Pujol (Institut Catala D'Oncologia), Barcelona

SW3 6JJ

Royal Marsden Hospital - Chelsea, London, London